October 3rd 2024
Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it priority review.
September 20th 2024
September 19th 2024
September 18th 2024
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
BLA Submitted for Liso-Cel Therapy in Patients With Large B-cell Lymphoma
December 19th 2019A Biologic License Application has been submitted for isocabtagene maraleucel, a chimeric antigen receptor T-cell agent, as a treatment for adult patients with relapsed or refractory large B-cell lymphoma after a minimum of 2 prior therapies, Bristol-Myers Squibb, the manufacturer, reported in a press release.
Read More
More VGPRs Seen With Zanubrutinib Versus Ibrutinib in Waldenstrom Macroglobulinemia
December 18th 2019In cohort 1 of the phase III ASPEN trial, zanubrutinib demonstrated a higher very good partial response rate and a more tolerable safety profile compared with ibrutinib in patients with Waldenström macroglobulinemia. However, the study missed its primary end point of statistically significant superiority in complete response and VGPR rates, according to a press release from BeiGene, Ltd, developer of the BTK inhibitor.
Read More
Single Dose CLR 131 Demonstrates Clinical Benefit in B-Cell Malignancies in Phase II Study
December 18th 2019Initial data from the phase II CLOVER-1 trial demonstrated an acceptable safety profile for CLR 131 in patients with relapsed/refractory B-cell malignancies, including multiple myeloma, Cellectar Biosciences, Inc., announced in a press release.
Read More
Treatment Options Expand for Older and Elderly Patients With AML
December 17th 2019In an interview with Targeted Oncology, Pinkal Desai, MD, discussed the latest advancements in the treatment landscape for patients with AML, particularly for the older population. She also highlighted emerging treatment options that undergoing investigation now in clinical trials.
Read More
Enasidenib/Azacitidine Triggers Significant Responses in Newly Diagnosed IDH2-Mutated AML
December 17th 2019Interim phase II trial data showed that the combination of enasidenib, an oral small molecule inhibitor of mutant IDH2 proteins, and azacitidine, significantly improves complete remission and overall responses in patients with newly diagnosed acute myeloid leukemia with IDH2 mutations compared with azacitidine alone, according to results presented at the 2019 American Society of Hematology Annual Meeting.
Read More
ELEVATE-TN Shows Acalabrutinib Is Well-Tolerated in CLL
December 17th 2019Jeff P. <a>Sharman</a>, MD, discusses the safety profile of acalabrutinib that was demonstrated in <a href="https://www.targetedonc.com/conference/ash-2019/patients-with-cll-treated-on-the-elevatetn-trial-experience-improved-pfs-with-acalabrutinib"><strong>the phase III ELEVATE-TN trial</strong></a>. The trial evaluated acalabrutinib as a single agent or in combination with obinutuzumab versus obinutuzumab plus chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia.
Watch
Hematology Experts Review Impactful Data from 2019 ASH Annual Meeting
December 13th 2019Following the 2019 ASH Annual Meeting, Targeted Oncology spoke with experts from various specialties in hematology. The experts highlighted some of the top abstracts from the meeting that will impact the way multiple myeloma, leukemias, MPNs, and lymphomas are treated.
Read More
Venetoclax Demonstrates Promising Responses in Waldenstrom Macroglobulinemia
December 12th 2019In an interview with Targeted Oncology, Jorge J. Castillo, MD, discussed the findings from the prospective phase II trial evaluating venetoclax in patients with Waldenström macroglobulinemia. He also addressed the unmet needs in this patient population and the next steps for research in the field.
Read More
In the phase III BELIEVE trial, clinically meaningful and durable transfusion burden reduction were observed with luspatercept in the majority of adult patients with β-thalassemia who require regular red blood cell. Additionally, dose levels were not associated with by incidence of adverse events, and these AEs decreases overtime without affecting treatment modification or continuation.
Read More
Bispecific Antibody Demonstrates Antitumor Activity in Heavily Pretreated NHL
December 11th 2019Treatment with REGN1979, a human anti-CD20 × anti-CD3 bispecific IgG4 antibody, showed high clinical activity and tolerability in heavily pretreated patients with relapsed/refractory B-cell non-Hodgkin lymphoma.<br />
Read More
Across Subtypes of B-cell NHL, REGN1979 Produces Promising Responses
December 11th 2019Heavily pretreated patients with relapsed/refractory B-cell non-Hodgkin lymphoma demonstrated antitumor activity when treated with varying dose levels of the human IgG4-based anti-CD20 × anti-CD3 bispecific monoclonalantibody, REGN1979.
Read More
CC-486 Maintenance Extends OS in Older Patients With Acute Myeloid Leukemia
December 10th 2019An extended media overall survival of 9.9 months was achieved with CC-486 maintenance treatment compared with placebo for older patients with acute myeloid leukemia in first remission, according to findings from the phase III QUAZAR AML-001 trial presented at the 2019 American Society of Hematology Annual Meeting.<br /> <br />
Read More
Acalabrutinib Sustains Benefit In Patients With R/R CLL After 42 Months
December 10th 2019Ongoing benefits of 42 months were observed with Bruton’s tyrosine kinase inhibitor acalabrutinib treatment in patients with relapsed/refractory chronic lymphocytic leukemia, according to long-term follow-up data from the phase I/II ACE-CL-001 study reported at the 2019 American Society of Hemetology Annual Meeting.
Read More
Vecabrutinib Shows Evidence of Clinical Activity in Patients With B-Cell Malignancies
December 10th 2019Stable disease status was achieved in patients with b-cell malignancies through treatment with vecabrutinib, a reversible, noncovalent Bruton’s tyrosine kinase inhibitor, without producing any grade ≥3 treatment-related adverse events, according to data presented at the 2019 American Society of Hematology Annual Meeting and Exposition.
Read More
42-Month Follow-Up Data of Acalabrutinib Monotherapy in R/R CLL
December 10th 2019<br /> Richard R. Furman, MD, professor of medicine, Morton Coleman, MD Distinguished Professor of Medicine, director, Chronic Lymphocytic Leukemia Research Center, Weill Cornell Medicine, and attending physician, NewYork-Presbyterian Hospital, discusses the 42-month follow-up data of acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia.
Watch
Long-Term Follow-Up Supports Early Use of Ibrutinib in CLL
December 10th 2019Data from up to 6 years of long-term follow-up shows better progression-free survival, overall survival, objective response rates, and sustained efficacy for patients with chronic lymphocytic leukemia who receive single-agent ibrutinib in earlier lines of treatment, including those with high-risk prognostic factors. According to the poster presented by Paul M. Barr, MD, Division of Hematology/Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, NY, during the 2019 American Society of Hematology Annual Meeting, first-line ibrutinib yielded deeper responses over time with 30% complete responses versus 10% to 12% CR for later lines of treatment.
Read More
Liso-Cel Shows Promising Clinical Activity and Safety in CLL/SLL
December 9th 2019Patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma who previously progressed on ibrutinib, responded well to treatment the CD19-directed CAR T-cell therapy lisocabtagene maraleucel and had manageable toxicity, according to updated findings from the phase I/II TRANSCEND CLL 004 study presented at the 2019 American Society of Hematology Annual Meeting and Exposition.
Read More